Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia.

CML is the most frequent chronic leukemia in Mexico. It mainly affects the economically active population (mean age 40), and the prognosis in our country has improved, emulating developed countries; however, the results depend on access to treatment and proper monitoring.